Expert Ratings for Alnylam Pharmaceuticals
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 26 analysts have published their opinion on Alnylam Pharmaceuticals (NASDAQ:ALNY) stock. The company has an average price target of $259.65, a decrease from the previous average price target of $272.36. The majority of the ratings are bullish.
October 16, 2023 | 7:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Alnylam Pharmaceuticals has received mostly bullish ratings from 26 analysts over the past 3 months. The average price target is $259.65, a decrease from the previous target of $272.36.
The majority of the 26 analysts have given Alnylam Pharmaceuticals a bullish rating, indicating a positive outlook for the company. However, the decrease in the average price target suggests a potential slowdown in the stock's growth. This could lead to a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100